1. Pink Sheet

The Xenazine Formula: Is it a Viable Model for Others?

 
• By Michael McCaughan

Despite its ultra-orphan indication, Xenazine is likely to provide a very attractive return on its development costs. It's a model that could work for other drugs-but only when several key factors work together.

Is it really a viable strategy to raise money to develop a drug solely to treat a condition as rare as Huntington’s chorea?

"Absolutely," says George Horner. Horner is the former CEO of Prestwick Pharmaceuticals Inc., who helped shepherd Xenazine (tetrabenazine) to market for the rare condition. Horner did not make the decision...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Agency Leadership

More from Pink Sheet

Non-User Fee Dollars Increased In US FDA’s Updated FY 2026 Budget Request

 
• By Derrick Gingery

The budget authority total, which is significantly higher than the amount floated in an April OMB draft document, suggests there may have been successful lobbying to increase FDA funding.

US ‘Most Favored Nation’ Pricing Could be Game Changer for Drug Access In Germany

 
• By Francesca Bruce

In this first in a series of articles looking at the potential impact of the MFN drug pricing policy on European pharmaceutical markets, EUCOPE’s Alexander Natz tells the Pink Sheet why the US policy underscores the importance of confidential net pricing.

ICH Targets RWE, Rare Diseases, Biosimilars, ATMPs In New Guideline Push

 
• By Vibha Sharma

The International Council for Harmonisation has identified four new topics that can benefit from global regulatory alignment, with timelines for initiating work to be determined later.